

Dated: April 2, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.
 [FR Doc. E7-6582 Filed 4-6-07; 8:45 am]
BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Pre-Knowledge of Early Hearing Detection and Intervention Program Process and Its Effect on Maternal Stress and Compliance With Follow-Up, Potential Extramural Project (PEP) 2007-R-07

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting.

Time and Date: 12 p.m.-4 p.m., May 16, 2007 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of PEP 2007-R-07, "Pre-Knowledge of Early Hearing Detection and Intervention Program Process and Its Effect on Maternal Stress and Compliance with Follow-Up."

For Further Information Contact: Juliana Cyril, M.P.H., Ph.D., Associate Director for Policy and Peer Review, CDC, 1600 Clinton Road, NE., Mailstop D72, Atlanta, GA 30333, telephone 404-639-4639.

The Director, Management Analysis and Services Office, has been delegated the

authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: April 2, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.
 [FR Doc. E7-6588 Filed 4-6-07; 8:45 am]
BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Epidemiological Studies of Epilepsy, Potential Extramural Project (PEP) 2007-R-05

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned SEP.

Time and Date: 12 p.m.-4 p.m., May 10, 2007 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of scientific merit of applications for "Epidemiological Studies of Epilepsy," PEP 2007-R-05.

For Further Information Contact: Juliana Cyril, M.P.H., Ph.D., Associate Director for Policy and Peer Review, CDC, 1600 Clifton Road, NE., Mailstop D-72, Atlanta, GA 30333, Telephone (404) 639-3098.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: April 2, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.
 [FR Doc. E7-6589 Filed 4-6-07; 8:45 am]
BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: NIOSH Education and Research Center, Program Announcement Number (PAR) 06-485

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following Meeting of the aforementioned Special Emphasis Panel:

Time and Date: 10 a.m.-1 p.m., April 24, 2007 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Purpose: The work groups which were convened at specific sites listed below advised and made recommendations to the Disease, Disability, and Injury Prevention and Control SEP: NIOSH Education and Research Center, PAR 06-485. Specifically, the SEP makes recommendations regarding policies, strategies, and funding.

TIMES, DATES, AND PLACES OF THE WORK GROUP MEETINGS

8 a.m.-5 p.m.	November 13, 2006 (Closed)	Women's Faculty Club on the University of California Berkeley campus 510-642-4175.
8 a.m.-5 p.m.	November 28, 2006 (Closed)	University of Alabama at Birmingham, Administration Building Penthouse, 701 20th Street South, 14th floor, Conference Room 1, 205-934-0771.
8 a.m.-5 p.m.	December 11, 2006 (Closed)	Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD 21205.
8 a.m.-5 p.m.	December 14, 2006 (Closed)	College of Public Health 13201 Bruce B. Downs Blvd Tampa, FL 33612.
8 a.m.-5 p.m.	January 9, 2007 (Closed)	Fitzsimons Campus, Nighthorse Campbell Building. Room 304 Denver, CO.
8 a.m.-5 p.m.	January 16, 2007 (Closed)	Coffman Memorial Union 300 Washington Ave. SE Minneapolis, MN 55455.
8 a.m.-5 p.m.	February 13, 2007 (Closed)	University Park Marriott 480 Wakara Way Salt Lake City, UT 84108 801-584-3312.

Matters to be Discussed: The SEP meeting will include the review, discussion, and evaluation of research grant applications in response to "NIOSH Education and Research Center," PAR 06-485.

For Further Information Contact: Dr. Charles N. Rafferty, Ph.D., B.S., Scientific Review Administrator, 1600 Clifton Road NE, MS E74, Atlanta, GA, 30333, telephone 404.498.2582.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for

both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: April 3, 2007.

Diane Allen,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E7-6591 Filed 4-6-07; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; The Board of Scientific Counselors (BSC), Centers for Disease Control and Prevention (CDC), National Center for Environmental Health (NCEH)/Agency for Toxic Substances and Disease Registry (ATSDR): Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), CDC and ATSDR announce the following meeting of the aforementioned committee:

Times and Dates: 8 a.m.–4:45 p.m., May 17, 2007. 8 a.m.–12 p.m., May 18, 2007.

Place: 1825 Century Boulevard, Atlanta, Georgia 30345.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 75 people.

Purpose: The Secretary, Department of Health and Human Services (HHS), and by delegation, the Director, CDC, are authorized under Section 301 (42 U.S.C. 241) and Section 311 (42 U.S.C. 243) of the Public Health Service Act, as amended, to: (1) Conduct, encourage, cooperate with, and assist other appropriate public authorities, scientific institutions, and scientists in the conduct of research, investigations, experiments, demonstrations, and studies relating to the causes, diagnosis, treatment, control, and prevention of physical and mental diseases and other impairments; (2) assist states and their political subdivisions in the prevention of infectious diseases and other preventable conditions and in the promotion of health and well being; and (3) train state and local personnel in health work. The BSC, NCEH/ATSDR provides advice and guidance to the Secretary, HHS; the Director, CDC, and Administrator, ATSDR; and the Director, NCEH/ATSDR, regarding program goals, objectives, strategies, and priorities in fulfillment of the agency's

mission to protect and promote people's health. The board provides advice and guidance that will assist NCEH/ATSDR in ensuring scientific quality, timeliness, utility, and dissemination of results. The board also provides guidance to help NCEH/ATSDR work more efficiently and effectively with its various constituents and to fulfill its mission in protecting America's health.

Matters To Be Discussed: An update on NCEH/ATSDR's Office of the Director; an update on Science and Public Health and Reports; an update on the Health Department Subcommittee, the Community and Tribal Subcommittee, and the Program Peer Review Subcommittee (PPRS) Reports and Discussion; a presentation on CDC's Web site redesign and the NCEH/ATSDR Web site; an update on Climate Change Initiative; a presentation on the Office of Tribal Affairs' Expert Panel Report; an update on issues from the Board; a discussion on the Office of Management and Budget Performance Assessment and Review Techniques goals and objectives; an update on the National Exposure Report; an update on Preparedness and Emergency Response priorities and portfolio; and a discussion on BSC—PPRS Draft Peer Review Report on ATSDR Site-Specific Activities.

Agenda items are tentative and subject to change.

FOR FURTHER INFORMATION CONTACT:

Sandra Malcom, Committee Management Specialist, NCEH/ATSDR, 1600 Clifton Road, Mail Stop E-28, Atlanta, Georgia 30303; telephone 404/498-0003, fax 404/498-0622; E-mail: smalcom@cdc.gov. The deadline for notification of attendance is May 4, 2007.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and NCEH/ATSDR.

Dated: April 2, 2007.

Elaine L. Baker,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E7-6585 Filed 4-6-07; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 1978N-0224 (formerly Docket No. 78N-0224); DESI 11853]

Trimethobenzamide Hydrochloride Suppositories; Withdrawal of Approval

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the resolution of issues concerning trimethobenzamide hydrochloride suppositories. This notice announces the withdrawal of approval of the new drug application (NDA) for Tigan (trimethobenzamide hydrochloride) Suppositories. The notice also declares that the marketing of unapproved trimethobenzamide hydrochloride suppository products is unlawful and subject to FDA regulatory action. FDA is taking these actions because trimethobenzamide hydrochloride suppositories lack substantial evidence of effectiveness.

ADDRESSES: Requests for an opinion on the applicability of this notice to a specific trimethobenzamide hydrochloride suppository product should be identified with Docket No. 1978N-0224 and reference number DESI 11853 and directed to the Office of Compliance, Division of New Drugs and Labeling Compliance (HFD-310), New Drugs and Labeling Team, Center for Drug Evaluation and Research, Food and Drug Administration, 11919 Rockville Pike, Rockville, MD 20852.

DATE: Effective May 9, 2007.

FOR FURTHER INFORMATION CONTACT:

Brian L. Pendleton, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

SUPPLEMENTARY INFORMATION:

I. Background

As part of its Drug Efficacy Study Implementation (DESI) program, in a notice published in the **Federal Register** on February 24, 1971 (36 FR 3435) (the 1971 notice), FDA announced the following conclusions regarding certain drug products that contain trimethobenzamide hydrochloride: (1) The products were probably effective for nausea and vomiting due to radiation therapy and vomiting due to emesis associated with operative procedures, labyrinthitis, or Meniere's syndrome; (2) they were lacking substantial evidence